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Acute respiratory tract infections (ARTIs) are the most com-
mon illnesses experienced by people of all ages worldwide.
Infants and young children are particularly vulnerable. The
pediatric population is disproportionately affected by ARTIs,
which represent a leading cause of morbidity and mortality
in this demographic. Lower respiratory tract infections
(LTRIs) are the second leading cause of death in children
younger than 5 years,1 and each year, 15% of all childhood
deaths are caused by pneumonia; most of these deaths are
preventable.1,2 Although the global incidence of ARTIs
appears similar on all continents, varying economic statuses
heavily skew themortality rate toward developing countries.
As a result, two-thirds of these deaths occur in southern Asia
and sub-Saharan Africa.3 Considering these epidemiological
data, the identiﬁcation of the etiological agents of ARTIs is an
essential requirement to establish an appropriate prevention
strategy.
The majority of ARTIs are thought to be caused by viruses,
such as human respiratory syncytial virus (hRSV), parain-
ﬂuenza virus, inﬂuenza virus, coronavirus, and rhinovirus.4
Unfortunately, in a signiﬁcant proportion of cases, the infec-
tious agent remains unknown because current diagnostic
methods have proven deﬁcient in detecting the etiology.
This observation suggests that unknown pathogens may be
circulating and may be responsible for a substantial number
of respiratory tract diseases.
In 2001 in the Netherlands, van den Hoogen et al reported
the discovery of a novel agent associated with upper and
LTRIs, human metapneumovirus (hMPV).5 The aim of this
review is to summarize current knowledge regarding hMPV
in terms of its epidemiology, pathogenesis, clinical manifes-
tations, respiratory complications, risk factors for the devel-
opment of severe disease, methods of diagnosis, and future
perspectives in therapy and vaccination.
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Abstract Acute respiratory tract infections (ARTIs) are themost common illnesses experienced by
people of all ages worldwide. In 2001, a new respiratory pathogen called human
metapneumovirus (hMPV) was identiﬁed in respiratory secretions. hMPV is an RNA virus
of the Paramyxoviridae family, and it has been isolated on every continent and from
individuals of all ages. hMPVcauses 7 to 19% of all cases of ARTIs in both hospitalized and
outpatient children, and the rate of detection in adults is approximately 3%. Symptoms
of hMPV infection range from a mild cold to a severe disease requiring a ventilator and
cardiovascular support. Themain risk factors for severe disease upon hMPV infection are
the presence of a high viral load, coinfection with other agents (especially human
respiratory syncytial virus), being between 0 and 5 months old or older than 65 years,
and immunodeﬁciency. Currently, available treatments for hMPV infections are only
supportive, and antiviral drugs are employed in cases of severe disease as a last resort.
Ribavirin and immunoglobulins have been used in some patients, but the real efﬁcacy of
these treatments is unclear. At present, the direction of research on therapy for hMPV
infection is toward the development of new approaches, and a variety of vaccination
strategies are being explored and tested in animal models. However, further studies are
required to deﬁne the best treatment and prevention strategies.
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Classiﬁcation
hMPV was ﬁrst isolated from nasopharyngeal aspirates of 28
hospitalized children and infants with ARTIs for which the
etiological agent could not be previously identiﬁed using
diagnostic assays for known respiratory viruses.5 It is an
enveloped, single-stranded, nonsegmented, negative-sense
RNA virus of the Paramyxoviridae family and Pneumovirinae
subfamily. This family is made up of the genus Pneumovirus,
which includes hRSV, and the genusMetapneumovirus, which
includes two viral species: hMPV and avian pneumovirus.
A whole genome analysis has shown that hMPV exists as
two genotypes, A and B, which are further divided into
subgroups A1, A2, B1, and B2.6 Subgroup A2 consists of two
clusters, A2a and A2b.
hRSV is the human pathogenmost closely related to hMPV.
The negative-strand RNA genomes of both viruses contain
frames that encode three envelope glycoproteins: the F
(fusion), G (attachment), and SH (short hydrophobic) pro-
teins. However, hMPV has certain differences from hRSV
concerning the absence of nonstructural genes and the
inversion of other genes.7
Epidemiology
Since it was ﬁrst detected, hMPV has been isolated on every
continent and from individuals of all ages. Seroprevalence
studies have revealed the presence of hMPV antibodies in
samples obtained in 1958, suggesting that the virus has been
circulating for at least the past 50 years.5 hMPV infections are
observed throughout the year, although a seasonal distribu-
tion has been thoroughly described.8–14 In temperate
climates, the epidemiological peak of hMPV is between
December and February and often coincides with or follows
the time of peak hRSV activity.
hMPV genotypes differ between communities, but similar
strains may be identiﬁed in various locations in different
years, and multiple lineages can exist in the same location
during the same period.6,10,15,16
Because hMPV presents as a respiratory infection, transmis-
sion is most likely attributed to infectious airborne droplets.17
The incubation period of the virus is between 4 and 6 days, and
excretion of the virus lasts between 2 and 14 days.8,18
hMPV causes 7 to 19% of all cases of ARTIs in both
hospitalized and outpatient children. The annual rate of
hospitalization associated with hMPV infections is 1 per
1,000 children, which is lower than that reported for hRSV
infections, but the same as the rate of hospitalization associ-
ated with the inﬂuenza virus.19 The rates of clinic and
emergency department visits due to hMPV infections are
55 per 1,000 and 13 per 1,000 children, respectively.19 The
rate of hMPV detection in adults is usually lower than that in
children and is approximately 3% in the general community.20
These data suggest that themajority of hMPV infections occur
early in childhood with high susceptibility rates in children
younger than 2 years old.21 Heikkinen et al have found that
the incidence of hMPV infections in children younger than
2 years is approximately twice the incidence observed in
children between 2 and 5 years of age and ten times higher
than the incidence among children older than 9 years.22
The ﬁrst hMPV infection appears to take place at the age of
6 months, although during this period, the documented
presence of maternally derived speciﬁc antibodies seems to
be protective against infection.23 Compared with infections
with hRSV, hMPV infections tend to occur in slightly older
children.8,24 However, seroprevalence studies revealed that
more than 90% of children younger than 5 years have already
been infected by hMPV.21 Most of the infected children were
previously healthy, although the risk of severe disease
appears higher in patients with an underlying medical
condition.8,10,25–27
Reports of hMPV infections in otherwise healthy adults are
relatively rare; almost 100% of young adults are seropositive
for hMPV with stable neutralizing titers.5 Despite this fact,
recurrences are most frequently observed in older adults
(65 years) and in patients with a comorbid illness, such as
chronic obstructive pulmonary disease (COPD), asthma,
cancer, or lung transplantation.28–30
Pathogenesis
The conventional model of hMPV attachment involves the
interaction of the G protein with a molecule or molecules on
the host cell surface.31 Then, the F glycoprotein promotes
fusion of the cell membrane with the virus envelope. Follow-
ing membrane fusion, viral ribonucleoprotein containing the
negative-sense viral RNA genome is released into the cyto-
plasm. Genomic RNA can serve as amatrix for viral transcrip-
tion and replication. The newly produced proteins associate
with viral genome copies to formnucleocapsids,whichwill be
incorporated into the virions as they bud from the surface of
the cell membrane.32
Infected cells may also form syncytia via a mechanism
similar to that observed for hRSV.33 Several animal models
havebeen developed to study hMPV infections, includingmice,
cotton rats, andprimates. hMPVreplicates tovaryingextents in
the upper and lower respiratory tracts of these animals, but
clinical symptoms have been observed only in chimpanzees.34
hMPV infection increases perivascular and peribronchiolar
inﬁltration and induces inﬂammatory changes and the forma-
tion of intra-alveolar foamy and hemosiderin macrophages.
Moreover, alveolar damage and smudge cells have been
observed.35 One study reported histopathologic changes dur-
ing hMPV infection in young patients.33 The bronchoalveolar
lavage samples and lung biopsy specimens of these patients
displayed epithelial cell degeneration or necrosis with
detached ciliary tufts and round red cytoplasmic inclusions,
frequent neutrophils, and mucus.
hMPV can persist for several weeks in the lungs, but there
is no evidence that it can cause a systemic infection. The
detection of hMPV RNA in the brain tissue of a patient who
died of encephalitis seems to conﬁrm this hypothesis.36
When compared with an infection with hRSV, an hMPV
infection in humans induces lower levels of inﬂammatory
cytokines such as interleukin (IL)-12, IL-8, IL-10, and tumor
necrosis factor-α (TNF-α).37
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Clinical Features
hMPVpreferentially targets ciliated epithelial cells and causes
a variety of clinical syndromes localized in the respiratory
tract. hMPV infection presents clinical manifestations that
make it difﬁcult to differentiate from infections with other
winter viruses, especially hRSV.38,39
hMPV infection is rarely asymptomatic in pediatric
patients. hMPV is the cause of 5 to 15% of upper respiratory
tract infections (URTIs) in children,22,38–40 is the second
leading cause of bronchiolitis in infants, and is the etiological
agent of a substantial proportion of LRTIs. Comparedwith the
children most commonly infected with hRSV, children who
develop an hMPV infection are older and present with a less
severe disease.22,38–40
URTIs associatedwith hMPV infection are characterized by
rhinitis, pharyngitis, conjunctivitis, and acute otitis media
(AOM). The duration of symptoms is usually less than a
week.41
LRTIs associated with hMPV infection frequently require
hospitalization. It is reported that 10% of hospitalizations
among children are attributable to hMPV infections.19,42–44
Clinical features include tachypnea; fever; cough; hypoxia;
wheezing; and chest X-ray abnormalities, such as inﬁltrates,
hyperinﬂation, and peribronchial cufﬁng.
As a respiratory pathogen, hMPV may be implicated in the
pathogenesis of AOM. The inﬂammatory reaction following
viral infection most likely leads to a partial or complete
obstruction of the Eustachian tubes, which increases the
risk for bacterial invasion of the middle ear.45,46 Williams
et al have found that one-third of the pediatric hMPV-
associated LRTIs have a diagnosis of AOM.21 In another study,
hMPV was detected in 6% of children who presented with
AOM as the primary diagnosis; no bacterial pathogen was
isolated from 25% of the patients in this study, suggesting that
hMPVmay be implicated as a unique infectious agent in cases
of AOM.47
hMPV infection has also been associated with febrile
seizures, rash, diarrhea, vomiting, and altered liver func-
tion.27 A few reports have suggested a connection with
central nervous system diseases, such as encephalitis48 and
status epilepticus.49
The overall rates of hMPV infection in adults are lower
than those described in children. Asymptomatic infections
in adults are common, accounting for at least 40% of cases,
and young adults usually experience a mild cold or inﬂu-
enza-like symptoms.50 However, elderly and immunocom-
promised patients may present with severe pneumonia
that may be fatal in some circumstances.28,51 In addition,
6 to 12% of COPD exacerbations have been associated with
hMPV, and the presence of an underlying lung disease is
common in patients hospitalized with hMPV infec-
tion.29,52,53 In long-term facilities, a high mortality rate
due to hMPV infection is reported. Boivin et al observed a
50% fatality rate in patients of a long-term care facility who
had a PCR-conﬁrmed hMPV infection and a 9.4% fatality
rate among elderly institutionalized persons with a possi-
ble hMPV infection.54
Respiratory Complications
hMPV infectionmaycause severemorbidity inboth thepediatric
and adult populations. Children admitted to a hospital may
develop a severe disease requiring an advanced ventilator and
cardiovascular support. Among hospitalized children, bronchi-
olitis is themost frequentdiagnosis uponadmission, followedby
pneumonia.55 Respiratory distress is the most common reason
for admission to the pediatric intensive care unit (PICU).55 A few
cases of apnea, shock, or status epilepticus have been reported.
Paget et al have compared children admitted to the PICU
with hMPV infections to those admitted with hRSV infec-
tions.56 They have observed that children with hMPV infec-
tions were signiﬁcantly older and presented less commonly
with bronchiolitis andmore commonlywith pneumonia than
those with hRSV infections. During the study period, hMPV
was the second leading cause of bronchiolitis after hRSV. Both
infections displayed a similar severity of disease.
In another study, 18% of pediatric patients hospitalized with
hMPV infections required PICU care, and 69% required respira-
tory support. Mechanical ventilation was necessary in 5% of
children, and noninvasive positive pressure ventilation, asmaxi-
mal support, was required in 9% of patients.57 Oxygen supple-
mentation was used in 55% of patients. In comparison to
previously healthy children, those who suffered from a chronic
medical condition needed respiratory noninvasive support for a
longer period andweremore frequently admitted to the PICU.57
Estrada et al reported the occurrence of apparent life-
threatening events (ALTEs) in three hMPV-infected patients
before hospital admission.58 An ALTE is deﬁned as cyanosis
associated with prolonged apnea spells. These episodes
involved three infants younger than 3 months.
Moreover, some fatal events have been reported. Schlap-
bach et al described the case of a 20-month-old healthy child
who died after experiencing acute respiratory distress syn-
drome (ARDS) due to hMPV infection.59 The patient developed
multiorgan failure and required venoarterial extracorporeal
membrane oxygenation (ECMO). The risk of ARDS is higher in
children affected by underlying conditions, especially prema-
turity and chronic lung diseases.19,60
Episodes of severe disease have been observed in adult
patients as well. It seems that hMPV can have a signiﬁcant
effect in some speciﬁc categories of fragile subjects. Elderly
and immunocompromised patients, including pregnant
women, are especially at risk. Although remarkably rare, a
few cases of severe disease in healthy adult individuals have
been observed. Contentin et al described a case of ARDS
secondary to hMPV infection in a healthy 58-year-oldwoman.
The patient required mechanical ventilation for 7 days and
was discharged from the hospital after 23 days.61
In general, because hMPV infection is quite common it
should be considered as a possibility for every patient with
respiratory failure admitted to the ICU.62
Risk Factors Related to Severe Disease
The severity of disease caused by hMPV infection may be
predicted by the coexistence of certain risk factors, some of
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which are associatedwith characteristics of the pathogen and
others of which depend on the clinical and demographic
features of the patient.
The correlation betweenviral load (VL) and clinical character-
istics of hMPV infection has been investigated in several studies.
Roussy et al observed that a high VL is associated with severe
disease: in effect, a VL higher than 1,000 copies/104 cp/mL is
independently associated with hospitalization and is correlated
with typical signs of LRTIs, such as rales on auscultation and use
of bronchodilators and inhaled glucocorticoids.63 These data
conﬁrmedﬁndings fromprevious studies,which associatedwith
a high VL with severe disease.64,65
In addition to these results, Peng et al observed that the VL
is correlated with the duration of illness.65 The number of
viral copies is signiﬁcantly different in patients who have
symptoms lasting between 6 and 11 days than in those with
symptoms of infection lasting less than 5 days.
To evaluate the connection between hMPV genotype and
the severity of respiratory infection, clinical features of
hospitalized children infected with hMPV have been corre-
lated with the detection of different hMPV genogroups. A
study by Vicente et al suggested that hMPV genotype A may
be more pathogenic than genotype B, because a diagnosis of
pneumonia is more commonly associated with genotype A
and the illness severity index is higher in patients with an
hMPV genotype A infection.66 In contrast, Pitoiset et al found
that the majority of pathological chest X-rays are observed in
patients infected by serotype B rather than A.42 Moreover,
Matsuzaki et al found that genotypes B1 and B2 are associated
with wheezing more frequently than genotype A2 is.67 Be-
yond the apparently conﬂicting results of these clinical
studies, the available data focusing on the correlation be-
tween disease severity and hMPV genotype indicate, for the
most part, a lack of signiﬁcant differences in terms of clinical
features in patients infected with different hMPV
lineages.13,42,66,68,69
Because of the overlapping seasonal distributions of hMPV
and hRSV, there is potential for coinfection. Many studies
evaluating hMPV infection have tested for the simultaneous
presence of other viruses. hRSV was detected in 5 to 17% of
patients infected with hMPV.25,70–72 Most results have not
described an exacerbation of the disease when multiple
pathogens were detected. However, one study reported a
10-fold increase in risk of admission to the PICU in children
coinfected with hRSV and hMPV, and the dual infection has
been described as being capable of augmenting severe bron-
chiolitis.73 On the other hand, bacterial coinfection is not
commonly observed during hMPV infections. hMPV appears
primarily as a respiratory pathogen, and the majority of
respiratory diseases are not associated with bacterial agents.
In contrast to these data, Madhi et al demonstrated that
the 9-valent pneumococcal conjugate vaccine may prevent
the development of hMPV-associated pneumonia. They
reported a 58% reduction in hospitalization for hMPV-associ-
ated LRTIs in vaccinated children. These results suggest
involvement of hMPV as a viral copathogen in bacterial
pneumonia. Further studies are necessary to clarify the
nature of this association.74
The immune status of infected patients is important in
determining the severity of illness. hMPV is capable of causing
severe infections in immunocompromised hosts, a phenome-
non that has been described for the majority of respiratory
viruses and is probably related to a reduced capability to
control viral replication in such individuals. Several studies
have suggested that hMPV is a common cause of ARTIs in the
adult and pediatric immunocompromisedpopulations, includ-
ing patients infected with human immunodeﬁciency virus
(HIV), subjects with a malignancy and hematopoietic stem
cell (HSC), or solid-organ transplant recipients.49,75–79 Some
fatalities have been reported in these populations.
In adult patients with hematological malignancies, 9% of
ARTIs have been attributed to hMPV,49 and hMPV has been
associated with 6% of ARTIs in lung transplant recipients.80
Among HSC transplant recipients, hMPV infection mortality
rates range from 10 to 80% in different studies. In themajority
of patients, hMPV is the only pathogen found, andmost of the
patients required hospitalization. The progression from up-
per to lower respiratory disease has been very frequently
observed.81–84
Among immunocompromised children, Chu et al reported
an hMPV-attributable mortality rate of 5%, and 23% of pa-
tients were classiﬁed as having a severe disease.85 Those who
developed severe pneumonia were more likely to be
neutropenic.
Moreover, hMPV has been detected in children with HIV
infection. In this group, it is difﬁcult to determine if the
disease is more severe.79
The association between children’s ages and disease severity
has also been investigated. In the pediatric population, being
between 0 and 5 months in age is linked to a higher risk of
hospitalization, whereas prematurity and low birth weight are
associated with a more frequent occurrence of severe disease in
hospitalized patients.86 Edwards et al conducted surveillance for
ARTIs among inpatient and outpatient children younger than
5 years in three U.S. states.19 They found a correlation between
hospitalization for hMPV infection and the presence of other
children between 5 and 17 years old in the home. Moreover,
members in households of hMPV-positive children fell ill signif-
icantly more and required more visits and drug prescriptions
than did those in households of hRSV-positive children, with a
frequency similar to that observed among members of house-
holds where inﬂuenza virus infections were present.71
The presence of an underlying medical condition is a risk
factor associated with increased disease severity. Hahn et al
found that the chronic lung diseases of prematurity (i.e., bron-
chopulmonary dysplasia, respiratory distress syndrome), an
anatomic or congenital lung disease (i.e., trachea-laryngomala-
cia), a congenital heart disease, a neuromuscular disorder (i.e.,
hypoxic-ischemic encephalopathy, cerebral palsy, traumatic
brain injury, spinal muscular atrophy), and trisomy 21 increase
the risk for a more severe disease.57 Moreover, children with
comorbidities who present with an hMPV infection are signiﬁ-
cantly more likely to be admitted to the PICU.57
In the case of asthma, a biunique association has been
observed. It is known that the previous presence of asthma is
a risk factor, predisposing an individual to severe respiratory
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disease during hMPV infection, but, in the acute phase, hMPV
itself can cause wheezing in young children.87–89 Bosis et al
found that almost 26% of children with hMPV infections
presented with wheezing,71 and Jartti et al reported that
hMPV has been detected in 8% of childrenwhowere admitted
to the hospital with exacerbation of wheezing.90 hMPV is also
associated with an exacerbation of asthma in adult patients
who required hospitalization.88 According to some authors,
hMPV plays a role not only in acute asthma exacerbation but
also in the development of recurrent wheezing and asthma in
the medium term.91–93 One retrospective study showed an
association between hMPV infection during infancy and the
subsequent diagnosis of asthma or another bronchial obstruc-
tive disease.91 The nature of this association remains to be
determined, because it is difﬁcult to establish a diagnosis of
asthma in the ﬁrst year of life when wheezing is commonly
observed during viral ARTIs. In light of these reﬂections,
further studies are required.
Among adult patients, hMPVcauses a more severe disease in
fragile elderly individuals, and the infection can result in death in
this population. Apart from advanced age, the major risk factor
associatedwith hMPV infection is the presence of an underlying
cardiopulmonary disease, especially COPD.8,28–30,50,53,54,88,94–96
Infections in patients with COPD frequently evolve to become
LTRIs, leading to development of fatal respiratory failure. The
fundamental reasons for the higher morbidity in older adults
have not been determined. The most likely explanation is that
aging causes impairment of innate and adaptive immunity.97
Moreover, inﬂammation as an exaggerated immune response to
viral infectionplays an important role in severedisease.98 Finally,
the existence ofmultiple hMPV lineagesmay lead to insufﬁcient
cross protection against different genotypes. The available data
focusing on this aspect have reported conﬂicting results.7,99
Additional studies are necessary to determine the nature of
age-related defects in the immune response during hMPV
infections and to establish if, after infection with a virus belong-
ing to a single subgroup, cross protection occurs. This last
question has a signiﬁcant implication for vaccine development.
Diagnosis
hMPV replicates poorly in conventional cell cultures and is
relatively difﬁcult to isolate.5,100–102 For these reasons,
reverse transcriptase polymerase chain reaction (RT-PCR)
and real-time RT-PCR have become the methods of choice
to detect hMPV.103
RT-PCR is a powerfulmethod that allows ampliﬁcation and
quantiﬁcation of this pathogen in clinical samples. The devel-
opment of multiplex RT-PCR has the advantage of supplying a
complete panel of respiratory viruses, which allows the
detection of coinfections with two or more pathogens, even
those with very low VLs.104–106
Direct immunoﬂuorescence or enzyme-linked immuno-
sorbent assays (ELISAs) are rapid methods to detect respira-
tory viruses, but they are not as sensitive as the molecular
techniques. Because infections with hMPV are universal,
serological tests used for the diagnosis of a recent infection
are only useful if fourfold increases in antibody titers or a
recent seroconversion are demonstrated.107,108 The option of
serological tests may be useful in epidemiological evaluations
to understand the worldwide seroprevalence of hMPV-spe-
ciﬁc antibodies in both pediatric and adult populations.109
Therapy against hMPV Infection
Currently, the available treatments for hMPV infection are
mostly supportive. For infants andchildrenwhoarehospitalized,
the primary therapies are oxygen supplementation and intrave-
nous hydration. Bronchodilators and corticosteroids are used
empirically, but no data support their efﬁcacy.18,57,110,111 Anti-
viral drugs are considered an option of last resort to treat a
severe hMPV infection.
At present, only ribavirin and immunoglobulins have been
used in humans for treatment of hMPV infections. Ribavirin is an
analogue of guanosine triphosphate (GTP) that may limit viral
transcription and lead to a reduction in the intracellular concen-
tration of GTP.112Moreover, it appears to have an immunomod-
ulatory effect in the containment of a viral infection.112
Immunoglobulins are available in two types of preparations,
speciﬁc and nonspeciﬁc: nonspeciﬁc polyclonal immunoglobu-
lins havebeen administered in severely affectedpatients, usually
along with ribavirin, with conﬂicting results.113 Most of the
treated cases were adults and children who were heavily
immunocompromised because of a malignancy or an HSC or
solid-organ transplant: all the patients received oral or, less
frequently, intravenous (IV) ribavirin, usually with IV immuno-
globulins.77,82–84,86,113–116 The results obtained by Chu et al in a
study of immunocompromised children affected by hMPVwere
negative: patientswho received antiviral treatment demonstrat-
ed a 22%mortality rate.85Dokos et al reported the occurrence of
fatal hMPV-associated pneumonia in a 10-year-old girl with
chronic graft-versus-host disease despite the administration of
IV ribavirin and IV immunoglobulins.82 Another retrospective
study, involving 145 hematologic adult patients infected with
paramyxoviruses, suggested that oral ribavirin therapy may not
improve clinical outcomes.114 Positive results have been
reported by other authors. Kitanovski et al presented the case
of a 2-year-old girl undergoing intensive chemotherapy for
Burkitt lymphoma who developed severe hMPV-associated
pneumonia.115 Rapid and complete recovery has been observed
after treatment with oral ribavirin and IV immunoglobulins.
Raza et al described a case of hMPV-associated pneumonia in a
lung transplant recipient presenting with respiratory failure and
sepsis syndrome.116 The patient was treated with IV ribavirin
with a successful outcome. Favorable results havebeen observed
among adult HSC transplant recipients as well.83,113
Recently, a humanized monoclonal antibody (mAb 338)
against the hMPV fusion protein has been developed. Studies
have shown its preventive and therapeutic efﬁcacy in
mice.117,118
New frontiers of therapy are directed toward the develop-
ment of drugs that act by inhibiting the fusion of the virus
with the cell membrane. One fusion inhibitor is currently
used in the case of HIV- infected patients and has shown
promising results against hRSV infection.119,120 Fusion
inhibitors against hMPV have only been employed in animal
Seminars in Respiratory and Critical Care Medicine Vol. 37 No. 4/2016
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models. Deffrasnes at al tested several inhibitor peptides that
have sequence homology with some domains of the hMPV F
protein. One of these peptides has shown efﬁcacy after
intranasal administration in mice; these mice appeared to
be protected from clinical symptoms and mortality due to
hMPV infection.121
Another interesting approach is based on the natural
phenomenon of RNA interference. There are some small,
noncoding, endogenous micro-RNA sequences that inhibit
the expression of speciﬁc genes by avoiding mRNA transla-
tion or by inducing mRNA cleavage. The use of exogenous
small interfering RNAs (siRNAs) that act similarly toward
targeted viral genes may produce an inhibitory effect. siRNAs
against the hMPV N and P proteins have been tested in vitro
with success.122
Vaccines
Several studies have focused their attention on developing
vaccines against hMPV. A perfect vaccine should be safe and
well tolerated and should produce a strong and long-lasting
immune response. A variety of vaccination strategies have
been explored and tested: inactivated viruses, live attenuated
viruses, and recombinant proteins.
Inactivated Vaccines
A formalin-inactivated hMPV vaccine is not a suitable vaccine
because it induces enhanced pulmonary disease and a Th2
cell response in animal models. Other inactivation methods
have been investigated for the development of a safe vaccine.
An opportunity is offered by a nanoemulsion-inactivated
hMPV vaccine that appears immunogenic and protective in
mice.123,124
Viral Protein-Based Vaccines
Subunit vaccines contain puriﬁed viral proteins, whichmay be
either full- or partial length. These proteins are usually assem-
bled in the form of virus-like particles (VLPs) or with the
addition of adjuvants that may enhance the immune
response.125 Several animal studies using hMPV protein-based
vaccines have been conducted. Among the viral proteins, the F
and G proteins have been used in the majority of cases.
The results obtained using G protein–based vaccines are
still controversial. Their role in the immunization process is
unclear. According to some authors, the glycoprotein G itself
has low immunogenicity.126 One possibility is that the com-
bination of this glycoprotein with some carriers reduces its
capability to promote an intense immune response.
On the other hand, immunization techniques that employ
the hMPV F protein–based vaccines are promising. There are
potential candidates for an hMPV vaccine that elicit speciﬁc
and strong humoral immunity in nonhuman primates,
although a rapid decay in antibody titers has been
observed.127,128 Further studies are required to identify the
most appropriate combination of carriers and to obtain
effective and long-lasting protection.
Live, Attenuated Vaccines
A live, attenuated vaccine may be recombinant or non-
recombinant. These vaccines may be produced during pas-
sages of cells under experimental stress such as cold or
chemical mutagenesis or by using viruses genetically modi-
ﬁed by reverse genetics. The major risk is in the potential
recovery of viral pathogenicity and subsequent disease
development in vivo. A perfect balance between attenuation
and immunogenicity is the ﬁrst goal. The majority of vaccine
candidates that used live, attenuated viruses have shown
good immunogenicity and have guaranteed protection
against subsequent infections in animal models.129 Recently,
awild-type recombinant hMPV strain has been approved as a
parent virus for the development of live, attenuated hMPV
vaccine candidates because it has been shown to be infectious
in a trial that involved 21 healthy adults.130
Conclusion
Since the discovery of hMPV, a large amount of data has been
obtained in numerous studies. Considerable progress has
been made toward understanding the molecular basis of its
replication, evaluating its clinical impact, characterizing the
disease pathogenesis, and improving diagnostic methods.
Despite this progress, other goals remain to be achieved.
More work is required to understand the role of hMPV
antigenic variability in human populations, to clarify the
mechanisms of innate and adaptive immunity after infection,
and to conﬁrm the existence of a real and long-lasting cross
protection against different hMPV genotypes after ﬁrst con-
tact with the virus. The results obtained from additional
studies focusing on these aspects may offer a true perspective
on the future of the development of effective therapeutic and
preventive measures against hMPV.
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